Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing.REDWOOD CITY, Calif., Dec. 27, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced that it has completed a series of financings that bolster the Company's financial health, reduce execution risk, and provide it with ...

First Time in the Company's HistoryREDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving positive free cash flow, a measure of financial health and another major milestone towards profitability. Dr. Waqaas Al-Siddiq, Biotricity's Founder & CEO, explains: "While continuing on our mission to produce transformative ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Nevada 001-40761 30-0983531 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.) FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2024 BIOTRICITY INC. (Exact name of registrant as specified in its charter) 203 Redwood Shores Parkway, Suite 600 Redwood City, Califo ...

Call Start: 16:30 January 1, 0000 4:51 PM ET Biotricity, Inc. (OTC:BTCY) Q2 2025 Earnings Conference Call November 15, 2024, 4:30 PM ET Company Participants Dr. Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - Chief Financial Officer Conference Call Participants Michael Davin - H.C. Wainwright Operator Greetings. And welcome to the Biotricity Conference Call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the formal presentation. [Operator Instructio ...

Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecurring techno ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or oth ...

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024. The ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 001-40761 Title of each class Trading Symbol(s) Name of each exchange on which registered BTCYOTCQB BIOTRICITY INC. ...

Biotricity, Inc. (NASDAQ:BTCY) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Operator At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. Unidentified Company Representative Earlier today, Biotricity issued its earnings press release for the period, which highlighted financial and operatio ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the fiscal year ended: March 31, 2024 Commission File Number: 000-56074 (Exact name of registrant as specified in its charter) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Sectio ...